FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:06:092 | Early achievement of remission confers better outcomes than low disease activity in both seropositive and seronegative patients with new-onset rheumatoid arthritis Clelia Zampaglione1|2, Ludovico De Stefano1|2, Federica Sabatelli1|2, Alessio D'Isanto1|2, Blerina Xoxi1|2, Antonio Manzo1|2, Carlomaurizio Montecucco1|2, Serena Bugatti1|2. | 1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 2Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
142 -
PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies Lianne S Gensler1, Helena Marzo-Ortega2, Vanessa Taieb3, Diana Voiniciuc4, Alexander Marten5, George Stojan6, Mindy Kim6, Paolo Marsico7, Martin Rudwaleit8 | 1Department of Medicine/Rheumatology, University of California San Francisco, USA; 2NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom; 3UCB Colombes, France; 4UCB Slough, United Kingdom; 5UCB Monheim am Rhein Germany; 6UCB Atlanta, USA; 7UCB Milan, Italy; 8University of Bielefeld, Klinikum Bielefeld Bielefeld Germany
17 -
PO:15:209 | Attainment of remission or lupus low disease activity state in single center Lupus Clinic Paola Tedoldi1|2, Silvia Ebe Lucia Della Pina1|2, Claudia Barison1|2, Chiara Orlandi1|2, Cecilia Nalli1, Micaela Fredi2, Ilaria Cavazzana1|2, Franco Franceschini1|2 | 1Rheumatology and Clinical Immunology Unit- ERN ReCONNET, ASST Spedali Civili of Brescia Brescia, Italy; 2Department of Clinical and Experimental Sciences, University of Brescia Brescia, Italy
27 -
CO:11:6 | Off-therapy remission in systemic lupus erythematosus: the BLys lupus flare index (BLyFI) as a decision tool for immunosuppressive therapy withdrawal in remitted patients Noemi Merra1, Anna Giorgia Osele1, Davide Ragno1, Greta Hulej1, Zahrà Rahmé1, Ilenia Anna Gennaio1, Filippo Vesentini1, Margherita Zen1, Luca Iaccarino1, Andrea Doria1 | Università degli Studi di Padova, Italy
150 -
PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; 7Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia
16 -
CO:12:2 | Circulating cell signatures of disease activity in ANCA-associated vasculitis using automated hematologic profiling analysis with Sysmex XN-9000®: preliminary results from a monocentric cohort Federica Davanzo1, Luca Iorio1, Veronica Davanzo2, Michela Pelloso2, Eleonora Fiorin1, Roberta Prevedello1, Francesca Tosato2, Martina Montagnana3, Roberto Padoan1, Andrea Doria1 | 1Rheumatology Unit, Department of Medicine DIMED, University of Padua Padova, Italy; 2Laboratory Medicine Unit, Biomedical Sciences Department-DSB, University of Padua Padova, Italy; 3Department of Medicine DIMED, University of Padua Padova, Italy
11 -
PO:15:224 | Measuring disease activity in Systemic Lupus Erythematosus patients: SLE-DAS usefulness in real-life setting Valeria Moretti, Fulvia Ceccarelli, Claudia Ciancarella, Cristina Garufi, Alessandra Ida Celia, Silvia Mancuso, Angelica Gattamelata, Simona Truglia, Francesca Romana Spinelli, Cristiano Alessandri, Fabrizio Conti | La sapienza Università di Roma, Italy
8 -
CO:01:3 | Which PRO reflects remission best? Bridging the gap between patient and physician in systemic lupus erythematosus Elena Ragusa1, Elisabetta Chessa2, Marta Paola Pireddu1, Fabio Congiu1, Giulia Rizzo1, Marianna Salis1, Alessandra Oliva1, Mattia Congia2, Alberto Cauli1|2, Matteo Piga1|2. | 1SC Reumatologia, Dipartimento di Scienze Mediche e Salute Pubblica, Università di Cagliari; 2SC Reumatologia, AOU Cagliari, Italy
195 -
PO:16:236 | Achieving a low disease activity state with a corticosteroid dose of 5 mg or less: observational study with anifrolumab in patients with systemic lupus erythematosus in Italy Alessandra Bortoluzzi1, Fulvia Ceccarelli2, Fabio Leo3, Paola Roccatagliata3, Chiara Tani4, Margherita Zen5 | 1Azienda Ospedaliera Universitaria Sant' Anna di Cona, Università di Ferrara Italy; 2Unità di Reumatologia, Università Sapienza Roma Italy; 3AstraZeneca S.p.a. Milano Italy; 4Università di Pisa e Azienda Ospedaliero Universitaria Pisana, Pisa Italy; 5Dipartimento di Medicina DIMED , Divisione di Reumatologia, Università di Padova, Italy
110 -
PO:16:232 | Belimumab step-down dose spacing in patients with systemic lupus erythematosus in persistent clinical remission: experience from a multicentric cohort Alice Bartoletti1, Laura Giudice1, Lorenza Maria Argolini1|2, Giuseppe Alvise Ramirez3, Luca Moroni3, Tommaso Schioppo4, Chiara Bellocchi5|6, Annalaura Fasiello6, Lorenzo Beretta6, Lorenzo Dagna3, Roberto Caporali1, Maria Gerosa1. | 1UO Clinica Reumatologica, ASST Gaetano Pini CTO, Milano, Italy; 2UOC Medicina fisica e riabilitazione specialistica, ASST Gaetano Pini CTO, Milano, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffa Milano Italy; 4Medicina Generale II, Servizio di Reumatologia, Ospedale San Paolo, ASST Santi Paolo Carlo, Milano, Italy; 5Department of Clinical Sciences and Community Health, University of Milan, Dipartimeto di Eccellenza 2023-2027, Milano, Italy; 6Referral Centre for Systemic Autoimmune DIseases, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
157 -
PO:06:083 | Clinical characteristics and outcomes of late- and young-onset rheumatoid arthritis in relation to autoantibody status Federica Sabatelli1|2, Ludovico De Stefano1|2, Clelia Zampaglione1|2, Lisa Bergianti1|2, Blerina Xoxi1|2, Antonio Manzo1|2, Carlomaurizio Montecucco1|2, Serena Bugatti1|2. | 1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 2Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
115 -
PO:35:234 | Sustained Vasculitis Quiescence and CS Reduction with Mepolizumab 100 mg Francesca Mascia1, Angelo Fassio2, Marco Zurlo1, Davide Chesini3, Francesco Pollastri2, Giovanni Adami2, Davide Gatti4, Maurizio Rossini4, Matteo Maule5, Gianentrico Senna1, Marco Caminati1 | 1University of Verona - Allergology and Clinical Immunology Verona, Italy; 2Policlinico G. B. Rossi - Rheumatology Verona, Italy; 3University of Verona - Faculty of Medicine and Surgery Verona, Italy; 4University of Verona - Rheumatology Verona, Italy; 5Policlinico G. B. Rossi - Allergology and Clinical Immunology Verona, Italy
13 -
PO:07:101 | Efficacy and safety of methotrexate in a cohort of patients affected by early-onset rheumatoid arthritis: a monocentric real-life study Carlo Cauli1, Martina Favretti2, Giulio Dolcini2, Vincenzo Ferraro1, Cristina Iannuccelli3, Fabrizio Conti1, Manuela Di Franco1 | 1UOC Reumatologia, Dipartimento di scienze cliniche internistiche anestesiologiche e cardiovascolari, Sapienza, Roma; 2Dipartimento di Medicina Molecolare, La Sapienza, Roma; 3UOC Reumatologia, AOU Policlinico Umberto I, La Sapienza, Roma, Italy
144 -
PO:15:218 | Evaluation of leukocyte expression of ecto-nucleotidase in patients with systemic lupus erythematosus Luca Rapino1, Simona Truglia1, Fulvia Ceccarelli1, Francesca Romana Spinelli1, Silvia Mancuso1, Giada La Spina1, Hector Rincon Arvalo2, Thomas Doerner2, Ana Luisa Stefanski2, Fabrizio Conti1. | 1La Sapienza Università di, Roma, - Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolare, Roma, Italy; 2Charité Universitätsmedizin - Department of Rheumatology and Clinical Immunology, Berlino, Germany.
117 -
PO:15:220 | Outcomes of extra renal flares in systemic lupus erythematosus: longitudinal analysis of a monocentric cohort Marco Oliva1, Giorgia Capozzo1, Giancarlo Cascarano1, Chiara Cardelli1, Dina Zucchi1, Angela Elia1, Elena Elefante2, Viola Signorini2, Chiara Stagnaro2, Chiara Tani1, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 2Rheumatology Unit, AOUP, Pisa, Italy.
129 -
PO:14:198 | Temporal Trends in LLDAS and DORIS Achievement in SLE: Impact of Evolving International Recommendations Laura Coladonato1, Marco Fornaro1, Angelica Napoletano1, Daniele Catamerò1, Giuseppe Lopalco1, Florenzo Iannone1 | 1UOC Reumatologia, Policlinico di Bari, DiMePre-J Bari, Italy
21 -
PO:16:235 | Anifrolumab in systemic lupus erythematosus: real-life experience of a single-center cohort Filippo Vesentini1, Luca Iaccarino1, Federico Arru2, Greta Hulej1, Anna Giorgia Osele1, Noemi Merra1, Davide Ragno1, Andrea Doria1, Margherita Zen1 | 1UOC Reumatologia, Dipartimento di Medicina DIMED, Università degli Studi di Padova; 2UO Medicina, ASL 3 Nuoro, Italy
124 -
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
146 -
PO:07:102 | Predicting success with baricitinib in rheumatoid arthritis: efficacy across ages and serological profiles Daniele Lini1, Matteo Colina2, Romina Andracco3, Francesca Ometto4, Viviana Ravagnani5, Alberto Lo Gullo6, Simone Parisi7, Antonella Farina8, Patrizia Del Medico9, Marino Paroli10, Olga Addimanda1, Alessandra Bezzi11, Federica Lumetti12, Aldo Biagio Molica Colella13, Davide Murgia14, Maddalena Larosa15, Aurora Ianniello16, Elena Bravi17, Marta Priora18, Palma Scolieri19, Alessandro Volpe20. | 1Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- Azienda Ospedaliera Universitaria-IRCCS di Bologna, Bologna; 2Rheumatology Service. Department of Medicine and Oncology, Ospedale Santa Maria della Scaletta, Imola; 3Imperia Hospital, Internal Medicine Unit, Rheumatology outpatient clinic, Imperia; 4Azienda ULSS 6 Euganea, Rheumatology Outpatient Clinic, Padova; 5Santa Chiara Hospital APSS Trento, Rheumatology Unit, Trento; 6ARNAS Garibaldi di Catania, Rheumatology Unit, Catania; 7Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Rheumatology Department, Torino; 8Ospedale A. Murri di Fermo, Internal Medicine Unit, Rheumatology outpatient clinic, Fermo; 9Civitanova Marche Hospital, Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche; 10Sapienza University of Rome, Polo Pontino, Department of Clinical, Anesthesiological and Cardiovascular Sciences, Latina; 11ASL Romagna Rimini, Internal Medicine and Rheumatology Unit, Rimini; 12Azienda USL of Modena and University Hospital Policlinico di Modena, Rheumatology Unit, Modena; 13Rheumatology Unit, Azienda Ospedaliera Papardo, Messina; 14ASL VC Ospedale S. Andrea, Unit of Rheumatology, Vercelli; 15Azienda Sanitaria Locale 3 Genova, Division of Rheumatology - Medical Specialties Department, Genova; 16ASL Novara, Rheumatology Outpatient Unit, Novara; 17Ospedale G. Da Saliceto, Rheumatology Unit, Piacenza; 18ASL CN1, Rheumatology Day Hospital and outpatient clinic, Mondovì (CN); 19Nuovo Regina Margherita Hospital, Department of Medical Specialties, Roma; 20IRCCS Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Negrar, Italy.
125 -
PO:07:103 | Tocilizumab use in patients with rheumatoid arthritis and malignancy: a monocentric experience Vittorio Dibenedetto1|2|3, Nicola Farina1|2, Nicola Boffini1|2, Alessandro Tomelleri1|2, Adriana Cariddi1|2, Elena Baldissera1|2, Marco Matucci-Cerinic1|2|3, Lorenzo Dagna1|2|3. | 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano, Italy; 2Inflammation, Fibrosis and Ageing Intitiative INFLAGE, IRCCS San Raffaele Hospital, Milano, Italy; 3Vita-Salute San Raffaele University, Milano, Italy.
126 -
PO:35:224 | Capturing What BVAS Misses: Patient-Reported Outcomes Reflect Disease Activity and Burden in EGPA Marta Codirenzi1, Federica Davanzo1, Luca Iorio1, Eleonora Fiorin1, Roberta Prevedello1, Roberto Padoan1, Andrea Doria1 | 1Unità di reumatologia, dipartimento di medicina DIMED,Università degli studi di Padova, Italy
11 -
PO:03:044 | Impact of Inflammatory Bowel Disease on Clinical Phenotype and Treatment Response in Patients with Psoriatic Arthritis Maria Morrone1, Maria Giannotta1, Vincenzo Venerito1, Greta Giulia Dipietrangelo1, Stefano Stano1, Florenzo Iannone1, Giuseppe Lopalco1 | 1Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J University of Bari, Bari, Italy
27 -
CO:10:2 | Common variable immunodeficiency patients complicated by autoimmune and inflammatory rheumatic manifestations reveal high frequency of genetic variants potentially linked to inborn errors of immunity Paolo Semeraro1, Micol Frassi1, Silvia Clara Giliani2, Franco Franceschini1, Paolo Airò1. | 1Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia; 2Medical Genetic Laboratory, ASST Spedali Civili of Brescia and University of Brescia, Italy
129 -
PO:35:227 | Long-term renal and survival outcomes in microscopic polyangiitis: data from an observational monocentric cohort Roberta Prevedello1, Federica Davanzo1, Luca Iorio1, Eleonora Fiorin1, Marta Codirenzi1, Roberto Padoan1, Andrea Doria1. | 1Unità di Reumatologia, Dipartimento di Medicina DIMED, Università degli Studi di Padova, Padova, Italy.
130 -
CO:02:2 | Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis: real world data from an Italian National Registry Valerio Fiorilli1, Francesca Romana Spinelli1, Florenzo Iannone2, Chiara Bazzani3, Alberto Cauli4, Rosario Foti5, Marcello Govoni6, Francesco Paolo Cantatore7, Fabiola Atzeni8, Roberto Caporali9, Marco Sebastiani10, Roberta Ramonda11, Serena Bugatti12, Elisa Gremese13, Maria Sole Chimenti14, Bruno Frediani15, Maurizio Rossini16, Angelo Semeraro17, Leonardo Santo18, Gianfranco Ferraccioli19, Giovanni Lapadula20, Fabrizio Conti1. | 1Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma; 2Dipartimento di Medicina di Precisione e Rigenerativa e Area Jonica, Università degli Studi Aldo Moro, Bari; 3ASST Spedali Civili di Brescia, Unità di Reumatologia ed Immunologia Clinica, Brescia; 4Dipartimento di Scienze Mediche e Sanità Pubblica, Università degli Studi di Cagliari; 5A.O.U. Policlinico S. Marco, UOS Reumatologia, Catania; 6Dipartimento di Scienze Mediche, Università di Ferrara; 7Unità di Reumatologia, Dipartimento di Medicina Specialistica, Università di Foggia; 8Dipartimento di Medicina Interna e Terapia Medica, UOC di Reumatologia, Università di Messina; 9Dipartimento di Scienze Cliniche e di Comunità, Università di Milano; 10Dipartimento di Medicina e Chirurgia, Università di Parma; 11Unità di Reumatologia, Dipartimento di Medicina, Università di Padova; 12Dipartimento di Medicina Interna e Terapia Medica, Università di Pavia, ; 13IRCCS Istituto Clinico Humanitas, Dipartimento di Scienze Biomediche, Milano; 14Dipartimento di Medicina dei Sistemi, Università degli Studi di Roma-Tor Vergata, ; 15Dipartimento di Medicina Clinica e Scienze Immunologiche, Università di Siena; 16Dipartimento di Medicina, Università di Verona; 17Presidio Ospedaliero Valle d'Itria, Unità Operativa di Reumatologia, Martina Franca; 18Presidio Ospedaliero "Mons. Dimiccoli", Unità Operativa Semplice di Reumatologia, Barletta; 19Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Roma; 20Gruppo Italiano di Studio sulla early Arthritis, GISEA, Bari, Italy.
166 -
CO:11:2 | Systemic lupus erythematosus with major neuropsychiatric involvement treated with anifrolumab: literature review and a case report Giulia Rizzo1, Fabio Congiu1, Elisabetta Chessa2, Marta Paola Pireddu1, Elena Ragusa1, Alessandra Oliva1, Marianna Salis1, Alberto Cauli1|2, Matteo Piga1|2 | 1SC Reumatologia, Dipartimento di Scienze Mediche e Salute Pubblica, Università di Cagliari Italy; 2SC Reumatologia, AOU Cagliari Italy
206 -
PO:35:218 | Switching the dose of mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European retrospective multicentre real-world study Edoardo Biancalana1, Irene Mattioli1, Emanuele Chiara2, Danilo Malandrino1, Maria Canfora1, Palmerini Miki1, Maria Paola Lisi1, Michela Gasparotto3, Paola Tomietto3, Maria Letizia Urban1, Giacomo Bagni1, Elena Silvestri1, Alessandra Bettiol3, Augusto Vaglio3, Giacomo Emmi2 | 1Department of Experimental and Clinical Medicine, University of Florence Firenze, Italy; 2Department of Medical, Surgery and Health Sciences, University of Trieste Trieste, Italy; 3Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Trieste, Italy; 4Department of Biomedical, Experimental and Clinical Sciences Mario Serio, University of Florence Firenze, Italy
18 -
CO:01:1 | Efficacy and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Veronica Batani1, Jasmin Mahajne1, Lorenzo Dagna1, Emanuel Della Torre1. | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale San Raffaele, Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University, Munich, Germany
269 -
PO:08:119 | Infusional Advantage: Rituximab’s Role in Enhancing Adherence in Multimorbid Rheumatoid Arthritis Marco Capodiferro1, Daniele Domanico1, Angelica Napoletano1, Giulia Righetti2, Patrizia Suppressa2, Vincenzo Venerito1, Giuseppe Lopalco1, Florenzo Iannone1, Fabio Cacciapaglia1|2 | 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Jonian Area DiMePRe-J University of Bari, Italy; 2Department of Medicine and Surgery, Miulli General Hospital Acquaviva delle Fonti - LUM University Casamassima Bari Acquaviva delle Fonti, Bari, Italy
12 -
PO:15:208 | Impact of disease control on organ damage accrual in patients with systemic lupus erythematosus with and extra-renal flares: a 12-month single-center longitudinal study Giorgia Capozzo1, Marco Oliva1, Giancarlo Cascarano1, Chiara Cardelli1, Dina Zucchi1, Chiara Stagnaro2, Viola Signorini2, Elena Elefante2, Chiara Tani1, Marta Mosca1. | 1Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale, Pisa, Italy; 2Azienda Ospedaliero Universitaria Pisana, U.O. Reumatologia, Pisa, Italy.
140 -
PO:18:276 | Use of anifrolumab in the treatment of difficult-to-treat manifestations in systemic lupus erythematosus Antonella Grimaldi1, Giuseppe Alessandrini2, Laura Quarta1, Maria Rita Ricciardi1, Daniela Costanza1, Clara Minerba1, Eugenio Quarta1 | 1UOC Reumatologia Verona; 2Specialista Dermatologo in Libera Professione, Italy
152
